Hongmei Wang1, Zhongxing Liao2, Yan Zhuang3, Ying Liu1, Lawrence B Levy2, Ting Xu2, Syed Wamique Yusuf4, Daniel R Gomez5. 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: dgomez@mdanderson.org.
Abstract
BACKGROUND: Preclinical and epidemiologic studies suggest that receipt of some cardiac medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, or aspirin may have antiproliferative effects in several types of cancer. The aim of this study was to estimate survival outcomes in patients receiving incidental cardiac medications during treatment for lung cancer, and to compare outcomes with those patients not receiving these medications. PATIENTS AND METHODS: We retrospectively reviewed 673 patients who had received definitive radiotherapy for stage III non-small-cell lung cancer (NSCLC). Cox proportional hazard models were used to assess associations between receipt of ACEIs, ARBs, β-blockers, or aspirin and locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). RESULTS: Multivariate analyses showed that ACEI receipt was associated with poorer LRPFS but had no effect on DMFS, DFS, or OS. Aspirin receipt was associated only with improved DMFS, and β-blocker receipt was associated with improved DMFS, DFS, and OS. CONCLUSION: Incidental receipt of ACEIs was associated with a higher prevalence of local failure, whereas receipt of either β-blockers or aspirin had protective effects on survival outcomes in this large group of patients with lung cancer. This finding warrants further clinical and preclinical exploration, as it may have important implications for treating patients with lung cancer who are also receiving cardiac medications.
BACKGROUND: Preclinical and epidemiologic studies suggest that receipt of some cardiac medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, or aspirin may have antiproliferative effects in several types of cancer. The aim of this study was to estimate survival outcomes in patients receiving incidental cardiac medications during treatment for lung cancer, and to compare outcomes with those patients not receiving these medications. PATIENTS AND METHODS: We retrospectively reviewed 673 patients who had received definitive radiotherapy for stage III non-small-cell lung cancer (NSCLC). Cox proportional hazard models were used to assess associations between receipt of ACEIs, ARBs, β-blockers, or aspirin and locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). RESULTS: Multivariate analyses showed that ACEI receipt was associated with poorer LRPFS but had no effect on DMFS, DFS, or OS. Aspirin receipt was associated only with improved DMFS, and β-blocker receipt was associated with improved DMFS, DFS, and OS. CONCLUSION: Incidental receipt of ACEIs was associated with a higher prevalence of local failure, whereas receipt of either β-blockers or aspirin had protective effects on survival outcomes in this large group of patients with lung cancer. This finding warrants further clinical and preclinical exploration, as it may have important implications for treating patients with lung cancer who are also receiving cardiac medications.
Authors: Terence T Sio; Pamela J Atherton; Levi D Pederson; W Ken Zhen; Robert W Mutter; Yolanda I Garces; Daniel J Ma; James L Leenstra; Jean-Claude M Rwigema; Shaker Dakhil; James D Bearden; Sonja J van der Veen; Apar K Ganti; Steven E Schild; Robert C Miller Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-02 Impact factor: 7.038
Authors: Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh Journal: Am J Clin Oncol Date: 2021-01-01 Impact factor: 2.339
Authors: Mark K Farrugia; Sung Jun Ma; David M Mattson; Leayn Flaherty; Elizabeth A Repasky; Anurag K Singh Journal: Am J Clin Oncol Date: 2020-12-01 Impact factor: 2.787